Several biomarkers have been tested during the last decade to predict the development of AKI and mortality in ICU patients including urinary tissue inhibitor of metalloproteinase 2 (TIMP-2), insulin-like growth factor-binding protein 7 (IGFBP-7) [16, 17], soluble receptor for advanced glycation end products (sRAGE) [18], soluble urokinase plasminogen activator receptor (suPAR) [19], and liver-type fatty acid-binding protein (L-FABP) [19]. Here, TIMP2 is linked to acute kidney injury.